Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.38 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL213174 | 0.99 | ITGB3 (0.39) | ITGB3ITGA2BAVPR1BCHEK2LMNA | |
| SCHEMBL213710 | 0.97 | ITGB3 (0.37) | ITGB3ITGA2BCHEK2LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL213384 | 0.96 | ITGB3 (0.38) | ITGB3ITGA2BCHEK2LMNAMAPK1 | |
| SCHEMBL213923 | 0.94 | CHEK2 (0.41) | AVPR1BCHEK2MET | |
| SCHEMBL213820 | 0.94 | HRH4 (0.39) | AVPR1BCHEK2LMNAMAPK1HIF1A | |
| SCHEMBL213243 | 0.93 | CHEK2 (0.35) | CHEK2LMNAMAPK1HIF1AHRH2 | |
| SCHEMBL214629 | 0.93 | HRH3 (0.39) | AVPR1B | |
| SCHEMBL216098 | 0.90 | KCNA5 (0.37) | AVPR1BCHEK2LMNAMAPK1HIF1A | |
| SCHEMBL215870 | 0.90 | CHEK2 (0.45) | AVPR1BCHEK2LMNAMAPK1HIF1A | |
| SCHEMBL214620 | 0.86 | CHEK2 (0.39) | ITGB3ITGA2BCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | ITGB3 2302/4885ITGA2B 1380/4885AVPR1B 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.